During this difficult time for families around the world, staying at home is vitally important to controlling the spread of COVID-19. And, we’re continually amazed and thankful to see all the ways families are finding ways to make a difference.

A message from TrialNet Chair Carla Greenbaum, M.D.

At TrialNet, the health and safety of our participants and research teams is always our top priority.

Elliot, a 17-year-old from a small village outside Bristol, recently completed treatment in the Abatacept Prevention Study. He is the first person in the United Kingdom (UK) to do so.